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A number of thienopyrimidines derivatives have shown potent vascu-
lar endothelial growth factor receptor 2 (VEGFR2) inhibition activity. 
111 Here, we present the synthesis of new 1-aryl-3-[4-(thieno[3,2-d) 
pyrimidin-4-yloxy)phenyl]ureas by promoting t he regioselective attack 
of the hydroxy group of the 4-aminophenol in the chlorine nucleophil ic 
displacement on two 4-chlorinated thieno[3,2-d]pyrimidines, obtain-
ing compounds la and 1b which were reacted with arylisocyanates tu 
give t he corresponding 1,3-d iarylureas 2a-f (see scheme). 
These compounds were evaluated for inhibition of VEGFR2 tyros-
ine kinase activity using enzymatic assays, and 2a- c showed good 
inhibition ability with IC50 values in t he range of hundreds of na-
nomolar. The rationale for the inhibition activity is also discussed 
using docking. To examine the activity of 2a- c in endothelial cells, 
human umbilical vein endothel ial cells (HUVECs) were cultured in 
the presence or absence of each compound in different concentra-
tions. A decrease in the proliferation of HUVECs was observed by 
the incorporation of BrdU quantified by ELISA assay. Given the estab-
lished role of VEGFR2 in proliferation and migration of endothelial 
cells, these molecu les are promising antiangiogenic agents that can 
be used for therapeutic purposes in pathologica l cond itions where 
angiogenesis is exacerbated, such as cancer. 
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Green Chemistry in Pharmaceutical Research-
Inspirations from Radical Reactions 
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Chemica l transformations in medicinal chemistry and pharmaceuti-
cal manufacturing have to meet ever more complex demands such 
as sustainability and selectivity in order to be applied to the multifac-
eted challenges of t oday.''' To address theses issues, radica I chemistry 
has been a largely neglected discipline. Herein, we would like to 
present three recent examples showing the suitability of metal-free 
radical reactions for pharmaceutica l purposes. Phenylazocarboxyi-
CJl~s 1, which are va luable building blocks for combinatorial synthesis, 
can be modified by nucleophilic substitution and radical reactions 
under mild conditions.'2•31 
Combin:~tori01l ~ynth!!~l~ 
with phcnylotz:tx:arbtu:yli\tn 
Cr oss.coupUng of ;:a~om.:ltlc.s · 
tc! gloutoctivc arylalion af omilinc:~. 
Nitrogen monollido in UKJ 
•ynthn lt of amino acids 
The synthesis of versatile 2-aminobiphenyls 2 has been achieved 
via a highly regioselective Gomberg-Bachmann arylation.141 Through 
a new type of the Meerwein arylation, nitrogen monoxide can used 
for the preparation of aromatic amino acids 3.'5' This process is also 
a potential tool for the recycl ing of NO occuring as waste gas on 
multi-ton-scale every day. 
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